Regeneron Pharmaceuticals, Inc. (REGN)

514.05
NASDAQ
Prev Close 508.31
Day Low/High 509.20 / 518.92
52 Wk Low/High 328.12 / 664.64
Exchange NASDAQ
Shares Outstanding 106.71B
Market Cap 54.24B
P/E Ratio 18.63
Div & Yield N.A. (N.A)
Amgen Shows a Bullish Breakout

Amgen Shows a Bullish Breakout

There is more upside to come for this stock.

Bullish Momentum for Regeneron

Bullish Momentum for Regeneron

Volatility has calmed down, and there are bullish signs.

Regeneron upgraded at Piper

Cramer: Here's the Reason for Allergan's Remarkable Run

Cramer: Here's the Reason for Allergan's Remarkable Run

Static doesn't work in this industry. Pipelines work.

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

Closing Bell: Active Oil Rigs Rise; Dow Gets Close to 20K but Falls Short

The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

Jim Cramer Sees Buying Opportunities in Praluent Patent Suit

After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.

Use Regeneron's Current Weakness to Go Long

Use Regeneron's Current Weakness to Go Long

Usually I prefer to buy strength as opposed to buying weakness, but I want to depart from my normal behavior with this biotech.

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

Regeneron Cholesterol-Lowering Drug Banned From U.S. Market

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

Cramer: Reviewing S&P's Hit-and-Miss Parade

Cramer: Reviewing S&P's Hit-and-Miss Parade

Even among the losers, buys are scarce.

Regeneron upgraded at BTIG

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

Cramer: With Trump, Everything's a Negotiation

Cramer: With Trump, Everything's a Negotiation

Just ask the drug companies or Boeing.

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Hillary isn't the only one who seems to favor workers over capital. Trump does, too.

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.

Markets Await October Jobs Report Friday

Markets Await October Jobs Report Friday

The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

FDA Puts Hold on Regeneron Pain-Drug Study

FDA Puts Hold on Regeneron Pain-Drug Study

Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

On days like this, the money just keeps sloshing around.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Jim Cramer: I’m Looking at the Biotechs

Jim Cramer: I’m Looking at the Biotechs

Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.

Regeneron Is Regenerating Lost Profits

Regeneron Is Regenerating Lost Profits

Investors should risk below $380 for now.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Regeneron Tries to Recover From Lows

Regeneron Tries to Recover From Lows

Prices pop today, but is this a reversal?

Regeneron May Cure the Market Blues

Regeneron May Cure the Market Blues

A potentially bullish pattern is setting up. 

How to Trade Regeneron's Pullback

How to Trade Regeneron's Pullback

Aggressive traders can go long REGN on the first up day.

Regeneron downgraded at Wells